Form 4: Rigel Pharmaceuticals CEO Acquires Shares and Stock Options

Rigel Pharmaceuticals CEO, Raul R. Rodriguez, acquired 42,300 shares of common stock and 63,400 stock options on January 29, 2025.

Summary

• Raul R. Rodriguez, CEO and President of Rigel Pharmaceuticals, acquired 42,300 shares of common stock through the vesting of a Restricted Stock Unit award.
• These shares will vest annually over three years, starting February 10, 2026.
• Mr. Rodriguez also acquired 63,400 stock options with an exercise price of $22.49.
• These options vest monthly over three years from January 29, 2025, contingent on his continued service to the company.
• The transactions were reported on January 31, 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management and shareholder interests. The vesting schedules suggest a long-term commitment from the CEO.

Positives

• The acquisition of shares and stock options by the CEO demonstrates confidence in the company's future performance.
• The vesting schedules for both the shares and options incentivize the CEO to remain with the company for the long term.

Future Outlook

The vesting schedules for the shares and options suggest a long-term commitment from the CEO to the company.

Industry Context

This type of equity-based compensation is common for executives in the pharmaceutical industry to align their interests with those of shareholders.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical sectors.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar equity-based incentives to attract and retain top talent.
• The vesting schedules described are typical for these types of awards, usually spanning three to four years to encourage long-term performance and retention.

Stakeholder Impact

• The acquisition of shares and options by the CEO could positively impact shareholder confidence.
• The vesting schedules incentivize the CEO to focus on long-term value creation, which benefits shareholders.

Key Dates

Keywords

Rigel Pharmaceuticals, Raul R. Rodriguez, stock options, restricted stock units, insider trading, executive compensation, equity awards